PeproMene Bio, Inc.

PeproMene Bio's BAFFR-CAR T Cell Therapy Shows Promise in Relapsed B-ALL Trial

- PeproMene Bio reports complete remission in the first patient treated with PMB-CT01 (BAFFR-CAR T cells) for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). - The Phase 1 trial at City of Hope showed minimal toxicity, with only low-grade cytokine release syndrome that resolved without intervention. - The patient, with CD19- and CD22-negative relapsed B-ALL, had limited therapeutic options prior to receiving PMB-CT01. - PMB-CT01, a first-in-class BAFFR-targeted CAR T-cell therapy, demonstrates potential in overcoming B-cell malignancies, supported by preclinical data.